Echo Therapeutics to Present at the JMP Securities Healthcare Conference
PHILADELPHIA, Sept. 20, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Sixth Annual JMP Securities Healthcare Conference.
Dr. Mooney will make a presentation to prospective corporate partners and investors on Tuesday, September 27th at 8:30 AM ET. The Company's presentation will be delivered at The St. Regis New York Hotel in New York City.
About Echo Therapeutics
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
For More Information:
Christine Olimpio
Director, Corporate Communications
(215) 717-4104
SOURCE Echo Therapeutics, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article